KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Treasury Shares (2017 - 2025)

Novartis Ag's Treasury Shares history spans 9 years, with the latest figure at $50.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 5.66% year-over-year to $50.0 million; the TTM value through Dec 2025 reached $50.0 million, down 5.66%, while the annual FY2025 figure was $50.0 million, 5.66% down from the prior year.
  • Treasury Shares for Q4 2025 was $50.0 million at Novartis Ag, down from $53.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $92.0 million in Q4 2022 and bottomed at $41.0 million in Q4 2023.
  • The 5-year median for Treasury Shares is $50.0 million (2025), against an average of $56.8 million.
  • The largest annual shift saw Treasury Shares surged 91.67% in 2022 before it tumbled 55.43% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $48.0 million in 2021, then skyrocketed by 91.67% to $92.0 million in 2022, then crashed by 55.43% to $41.0 million in 2023, then grew by 29.27% to $53.0 million in 2024, then dropped by 5.66% to $50.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVS's Treasury Shares are $50.0 million (Q4 2025), $53.0 million (Q4 2024), and $41.0 million (Q4 2023).